
1. histopathology. 2018 jun;72(7):1156-1163. doi: 10.1111/his.13475. epub 2018 mar
9.

immunohistochemical assessment diagnostic utility pd-l1: preliminary 
analysis anti-pd-l1 antibody (sp142) lymphoproliferative diseases with
tumour non-malignant hodgkin-reed-sternberg (hrs)-like cells.

sakakibara a(1)(2), kohno k(1), eladl ae(1)(3), klaisuwan t(1)(4), ishikawa
e(1)(5), suzuki y(1), shimada s(1), nakaguro m(1), shimoyama y(1), takahara t(6),
kato s(7), asano n(8), nakamura s(1), satou a(6).

author information: 
(1)department pathology laboratory medicine, nagoya university hospital,
nagoya, japan.
(2)department pathology, okazaki city hospital, okazaki, japan.
(3)department pathology, faculty medicine, mansoura university, mansoura,
egypt.
(4)department pathology, faculty medicine, chiang mai university, chiang
mai, thailand.
(5)department gastroenterology hepatology, aichi medical university
hospital, nagakute, japan.
(6)department surgical pathology, aichi medical university hospital, nagakute,
japan.
(7)department pathology molecular diagnostics, aichi cancer center
hospital, nagano, japan.
(8)department clinical laboratory, nagano prefectural suzaka hospital, nagano,
japan.

aims: programmed death 1 (pd1)/pd1 ligand (pd-l1) axis plays important
role tumour cells escape immune control. pd-l1 immunohistochemistry 
useful predictor immunotherapy response, still used widely the
diagnostic setting. describe results using pd-l1 immunohistochemistry
during routine diagnostics lymphoma.
methods results: ninety-one lymphoproliferative disease cases sharing tumour 
and non-malignant hodgkin-reed-sternberg (hrs)-like cells without
epstein-barr virus (ebv) association investigated immunohistochemistry
for pd-l1 (clone sp142). pd-l1 expression present 5% tumour
or non-malignant hrs-like cells 100% ebv+ classical (c) hodgkin lymphoma
(hl) (n = 10) ebv-negative nodular sclerosis chl (n = 8); 40% ebv+ diffuse
large b cell lymphoma, otherwise specified (dlbcl-nos) (n = 20); 4% of
nodal peripheral cell lymphoma follicular helper cell type (ptcl-tfh)
(n = 22). contrast, nodular lymphocyte-predominant hl (n = 4), lymphocyte-rich
chl (n = 6), ebv+ hyperplasia (n = 8), plasmablastic lymphoma (n = 3) and
anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (n = 5) seldom
exhibited pd-l1 large cells. assessing pd-l1 positivity tumour and
non-malignant large cells helpful differentiating chl versus nodal
ptcl-tfh (p < 0.0001) ebv+ dlbcl-nos (p = 0.0052) ebv+ dlbcl-nos
versus nodal ptcl-tfh (p = 0.0052), pd-l1 expression indicating first
diagnosis sets.
conclusion: immunohistochemical evaluation pd-l1 expression tumour and
non-malignant hrs-like large cells may useful assessing either immune
escape immunodeficiency pathogenesis.

© 2018 john wiley & sons ltd.

doi: 10.1111/his.13475 
pmid: 29380399  [indexed medline]

